Company overview
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells.
News Center
-
01-052022ImmuneOnco started Phase Ib/II Clinical Study of IMM01: An IMM01 combined with azacitidine clinical trial completed the first patient enrollment and dosingOn January 5, 2022, Shanghai, China, ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd.， (hereinafter referred to as "Im......See details
-
01-042022ImmuneOnco grandly held the groundbreaking ceremony of its headquarter and biopharmaceutical manufacturing baseThe first sod was turned in the morning on the first working day of the new year (January 4, 2022). The groundbreaking......See details
-
12-312021ImmuneOnco announced the completion of nearly 100 million U.S. dollars in cross-round financingOn December 31, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") ann......See details